Related Experiment Videos
[Clinical effect of cefotiam on otorhinolaryngologic infections]
Abstract:
The clinical effectiveness and safety of cefotiam (CTM) in infectious diseases in the field of otorhinolaryngology was evaluated from 30 patients (otitis media 18, pharyngeal infection 4, chronic paranasal sinusitis 1, esophagitis 1, acute bronchitis 1, others 4). Side effect (fever, nausea) was found in a 14 years old male patient. Skin test revealed positive in 1 patient. These cases were excepted from evaluating clinical effectiveness of CTM. In 28 patients, the overall ratio of clinical effectiveness was 60.7%. In patients of otitis media, the clinical effectiveness ratio was 41.2%, whereas the ratio was 75.0--100% in patients of other diseases. In particular, the clinical effect was fair or poor in patients to whom the drug was given only once a day. These results suggest that this chemotherapeutic drug should be administered at least twice a day, particularly to the patients of otitis media. The bacteriological response to CTM was evaluated from 53 strains, isolated from 28 patients before treatment. Eradication rate of bacteria was 60.4%. No abnormal laboratory findings, relating to the drug, were observed after treatment.
Insights
Cefotiam (CTM) showed 60.7% effectiveness in otorhinolaryngology infections, but efficacy decreased with once-daily dosing. Twice-daily administration is recommended, especially for otitis media.
Area of Science:
- Pharmacology
- Infectious Diseases
- Otorhinolaryngology
Context:
- The study evaluated cefotiam (CTM) in treating various infectious diseases within the otorhinolaryngology field.
- A total of 30 patients with conditions including otitis media, pharyngeal infections, and sinusitis were included.
Purpose:
- To assess the clinical effectiveness and safety of cefotiam (CTM) in patients with otorhinolaryngological infections.
- To determine the optimal dosing frequency for CTM based on clinical outcomes.
Summary:
- Overall clinical effectiveness of CTM was 60.7% in 28 patients, with higher rates (75-100%) in non-otitis media cases compared to otitis media (41.2%).
- Adverse effects were minimal, noted in one patient (fever, nausea) and one with a positive skin test.
- Bacteriological eradication rate was 60.4% for 53 strains isolated before treatment. No drug-related laboratory abnormalities were observed.
Impact:
- Results suggest that cefotiam should be administered at least twice daily, particularly for otitis media patients, to improve clinical outcomes.
- Findings provide evidence-based recommendations for cefotiam dosing in specific ENT infections.
- The study highlights the importance of dosing frequency in antibiotic efficacy for otorhinolaryngological infections.